Sugi Predict

Sugi Predict / Compounds / SCHEMBL3330660

SCHEMBL3330660

SCHEMBL3330660

CCOC(=O)[C@H]1CCCN1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PRCP P42785 2/20 0.45
▸ DPP7 Q9UHL4 2/20 0.40
▸ SCN4A P35499 1/20 0.40
▸ NOS2 P35228 2/20 0.39
▸ NOS3 P29474 1/20 0.39
▸ NOS1 P29475 1/20 0.39
▸ SLC6A2 P23975 3/20 0.39
▸ SLC6A3 Q01959 3/20 0.39
▸ SLC6A4 P31645 2/20 0.39
▸ DPP4 P27487 1/20 0.39
▸ FAP Q12884 1/20 0.39
▸ DPP8 Q6V1X1 1/20 0.39
▸ DPP9 Q86TI2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ PPM1B O75688 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ PPP1CC P36873 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10829027 1.00 PRCP (0.45) PRCPDPP7SCN4ANOS2NOS3
SCHEMBL133135 1.00 PRCP (0.45) PRCPDPP7SCN4ANOS2NOS3
SCHEMBL115996 1.00 PRCP (0.45) PRCPDPP7SCN4ANOS2NOS3
Ammonia Solution, Strong SCHEMBL6516951 0.98 PRCP (0.44) PRCPDPP7SCN4ANOS2NOS3
Hydrochloric Acid SCHEMBL1073479 0.98 PRCP (0.44) PRCPDPP7SCN4ANOS2NOS3
Hydrochloric Acid SCHEMBL3530351 0.98 PRCP (0.44) PRCPDPP7SCN4ANOS2NOS3
Hydrochloric Acid SCHEMBL133134 0.98 PRCP (0.44) PRCPDPP7SCN4ANOS2NOS3
Azetidine SCHEMBL18917062 0.96 PRCP (0.43) PRCPDPP7SCN4ANOS2NOS3
SCHEMBL135813 0.94 SLC6A2 (0.44) PRCPSLC6A2SLC6A3SLC6A4ALDH1A1
SCHEMBL1929065 0.94 SLC6A2 (0.44) PRCPSLC6A2SLC6A3SLC6A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092091-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE LIGANDS Humanwell Pharmaceutical US 2025-03-20 — — US disclosed
US-12215173-B2 Kappa opioid receptor peptide amide ligands HUMANWELL PHARMACEUTICAL US, Inc. (US) 2025-02-04 — — US disclosed
CN-113024434-B Buvaracetam Process for the preparation of intermediates 上海科胜药物研发有限公司 2024-09-06 — — CN disclosed
EP-3554503-B1 INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) UNIV TEXAS (US) 2023-10-04 — — EP disclosed
CN-114615976-A Kappa opioid receptor peptide amide agonists 人福医药美国公司 2022-06-10 — — CN disclosed
US-11192878-B2 Piperidine-2,6-dione derivative and use thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2021-12-07 — — US disclosed
CN-113024434-A Preparation method of brivaracetam intermediate 上海科胜药物研发有限公司 2021-06-25 — — CN disclosed
US-20210040150-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) 2021-02-11 — — US disclosed
WO-2021026492-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS Humanwell Pharmaceutical US (US) 2021-02-11 — — WO disclosed
US-20200062730-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2020-02-27 — — US disclosed
EP-1161240-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Du Pont Pharmaceuticals Company (US) 2001-12-12 — — EP disclosed
EP-1158980-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Du Pont Pharmaceuticals Company (US) 2001-12-05 — — EP disclosed
EP-1156807-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Du Pont Pharmaceuticals Company (US) 2001-11-28 — — EP disclosed
EP-1140086-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Du Pont Pharmaceuticals Company (US) 2001-10-10 — — EP disclosed
EP-1140087-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Du Pont Pharmaceuticals Company (US) 2001-10-10 — — EP disclosed
WO-2000035451-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 — — WO disclosed
WO-2000035449-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 — — WO disclosed
WO-2000035452-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 — — WO disclosed
WO-2000035454-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 — — WO disclosed
WO-2000035453-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062730-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF CRBN, PDCD11, CD47 PRCP 2862/4885DPP7 2285/4885SCN4A 3928/4885
US-11192878-B2 Piperidine-2,6-dione derivative and use thereof CRBN, PDCD11, CD47 PRCP 2291/4885DPP7 2149/4885SCN4A 4010/4885
US-20250092091-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE LIGANDS OPRK1, OPRL1, OPRD1 PRCP 870/4885DPP7 941/4885SCN4A 1083/4885
US-12215173-B2 Kappa opioid receptor peptide amide ligands OPRK1, OPRL1, OPRD1 PRCP 870/4885DPP7 941/4885SCN4A 1083/4885
US-20210040150-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS OPRK1, OPRL1, OPRD1 PRCP 825/4885DPP7 814/4885SCN4A 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.